Share Email Print
cover

Proceedings Paper

Photodynamic therapy using 5-aminolevulinic acid-induced photosensitization: current clinical status
Author(s): Stuart L. Marcus; Allyn L. Golub; D. Geoffrey Shulman
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy using 5-aminolevulinic acid-induced photosensitization (ALA PDT) via endogenous protoporphyrin IX (PpIX) synthesis has been reported as efficacious, using topical formulations, in the treatment of a variety of dermatologic diseases including superficial basal cell carcinoma, Bowen's disease, and actinic (solar) keratoses. Application of ALA PDT to the detection and treatment of both malignant and non-malignant diseases of internal organs has recently been reported. Local internal application of ALA has been used for the detection, via PpIX fluorescence, of pathological conditions of the human urinary bladder and for selective endometrial ablation in animal model systems. Systemic, oral administration of ALA has been used for ALA PDT of superficial head and neck cancer and of colorectal cancer. This paper reviews the current clinical status of ALA PDT.

Paper Details

Date Published: 1 March 1995
PDF: 7 pages
Proc. SPIE 2371, 5th International Photodynamic Association Biennial Meeting, (1 March 1995); doi: 10.1117/12.203429
Show Author Affiliations
Stuart L. Marcus, DUSA Pharmaceuticals, Inc. (United States) and (Canada)
Allyn L. Golub, Guidelines Inc. (United States)
D. Geoffrey Shulman, DUSA Pharmaceuticals, Inc. (United States) and (Canada)


Published in SPIE Proceedings Vol. 2371:
5th International Photodynamic Association Biennial Meeting
Denis A. Cortese, Editor(s)

© SPIE. Terms of Use
Back to Top